Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (161-170 of 199) with videos related to

Pageof 20
Sort By:
Nature Cell Biology|May 20, 2020
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistanceMingjun Bi, Zhao Zhang, Yi-Zhou Jiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 17, 2017
Embryonic transcription factor SOX9 drives breast cancer endocrine resistanceRinath Jeselsohn, MacIntosh Cornwell, Matthew Pun, et al.
Cancer Research|September 28, 2016
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical OutcomesAndriy Marusyk, Doris P Tabassum, Michalina Janiszewska, et al.
Cancers|April 3, 2021
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Mario Giuliano, Fabiola Giudici, et al.
Cancer Research|December 8, 2017
Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional AxisYanming Wu, Zhao Zhang, Mauro E Cenciarini, et al.
NPJ Breast Cancer|May 28, 2021
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft modelsJamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2011
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivoKristen L Meerbrey, Guang Hu, Jessica D Kessler, et al.
Neoplasia (New York, N.Y.)|July 14, 2014
Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistanceNagireddy Putluri, Suman Maity, Ramakrishna Kommagani, et al.
Cell Reports|July 19, 2023
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancerXiaoyong Fu, Resel Pereira, Chia-Chia Liu, et al.
Journal of Clinical Medicine|October 27, 2019
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast CancerHariprasad Thangavel, Carmine De Angelis, Suhas Vasaikar, et al.
Pageof 20

Showing results (161-170 of 199) with videos related to

Sort By:
Pageof 20
Nature Cell Biology|May 20, 2020
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistanceMingjun Bi, Zhao Zhang, Yi-Zhou Jiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 17, 2017
Embryonic transcription factor SOX9 drives breast cancer endocrine resistanceRinath Jeselsohn, MacIntosh Cornwell, Matthew Pun, et al.
Cancer Research|September 28, 2016
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical OutcomesAndriy Marusyk, Doris P Tabassum, Michalina Janiszewska, et al.
Cancers|April 3, 2021
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Mario Giuliano, Fabiola Giudici, et al.
Cancer Research|December 8, 2017
Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional AxisYanming Wu, Zhao Zhang, Mauro E Cenciarini, et al.
NPJ Breast Cancer|May 28, 2021
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft modelsJamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2011
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivoKristen L Meerbrey, Guang Hu, Jessica D Kessler, et al.
Neoplasia (New York, N.Y.)|July 14, 2014
Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistanceNagireddy Putluri, Suman Maity, Ramakrishna Kommagani, et al.
Cell Reports|July 19, 2023
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancerXiaoyong Fu, Resel Pereira, Chia-Chia Liu, et al.
Journal of Clinical Medicine|October 27, 2019
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast CancerHariprasad Thangavel, Carmine De Angelis, Suhas Vasaikar, et al.
Pageof 20